Roche said this week that William Burns will not stand for re-election to the board of directors. The company also said that it has proposed that Christoph Franz be elected as chairman of the board, and the remaining members of the board should be re-elected.

The remaining board members include Andre Hoffman; Andreas Oeri; Pius Baschera; John Irving Bell; Paul Bulcke; DeAnne Julius; Severin Schwan; Peter Voser; Arthur Levinson; and Beatrice Weder di Mauro.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.